MRMD (MariMed) Other Long-Term Liabilities: $6.9 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is MariMed Other Long-Term Liabilities?

MariMed MRMD +0.61% Other Long-Term Liabilities is $6.9 Mil as of Jun. 2026. The stock has 4 warning signs investors should review.

MariMed's other long-term liabilities for the quarter that ended in Jun. 2026 was $6.9 Mil.

MariMed's quarterly other long-term liabilities declined from Dec. 2025 ($14.7 Mil) to Mar. 2026 ($6.9 Mil) but then increased from Mar. 2026 ($6.9 Mil) to Jun. 2026 ($6.9 Mil).

MariMed's annual other long-term liabilities stayed the same from Dec. 2023 ($19.1 Mil) to Dec. 2024 ($19.1 Mil) but then declined from Dec. 2024 ($19.1 Mil) to Dec. 2025 ($14.7 Mil).

MariMed Other Long-Term Liabilities Related Terms

MariMed Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for MariMed's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MariMed Other Long-Term Liabilities Chart

MariMed Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 37.83 37.83 19.10 19.10 14.73

MariMed Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.83 14.83 14.73 6.93 6.93

MariMed Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of $6.9 Mil mean?
MariMed (MRMD) has a Other Long-Term Liabilities of $6.9 Mil as of Jun. 2026. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on MariMed and its competitors.
Is MariMed's Other Long-Term Liabilities too high?
MariMed's current Other Long-Term Liabilities is $6.9 Mil.
How does MariMed's Other Long-Term Liabilities compare to RMTI and INIS?
MariMed's Other Long-Term Liabilities of $6.9 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Drug Manufacturers company?
A good Other Long-Term Liabilities depends on the Drug Manufacturers industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on MariMed and its competitors. MariMed's current Other Long-Term Liabilities is $6.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MariMed stock overvalued right now?
Based on GuruFocus' analysis, MariMed (MRMD) is currently considered Possible Value Trap. The stock's GF Value™ is $0.14, compared to a current price of $0.08 — trading 40.7% below its estimated fair value. The current Other Long-Term Liabilities is $6.9 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For MariMed (MRMD), the current Other Long-Term Liabilities is $6.9 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MariMed Business Description

Other Exchanges MRMD:Canada
Address 10 Oceana Way, Floor 2, Norwood, MA, USA, 02062
MariMed Inc is a multi-state cannabis operator in the United States dedicated to improving lives every day through its high-quality products. The company develops, owns, and manages seed to sale state-licensed, regulatory-compliant facilities for the cultivation, production, and dispensing of medicinal and adult-use cannabis. It has created and continues to develop its own brands of cannabis flower, concentrates, edibles, and other precision-dosed products utilizing its proprietary strains and formulations. The company also licenses its proprietary brands, along with other top cannabis products, in select domestic markets. Its operations are conducted in compliance with applicable state and local laws and regulations in the jurisdictions in which it operates.